Presentation Scheduled for Thursday, May 15th at 11:10am PT
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Bank of America 2008 Health Care Conference in Las Vegas, Nevada Mr. Weiss' presentation, which will take place on Thursday, May 15th at 11:10am PT, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965
E-mail: DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director - Investor Relations of Keryx Biopharmaceuticals, Inc., +1-212-531-5965, Web site: http://investors.keryx.com/
|